HIV Prevention R&D Trial Participants by Region in 2018 (thousands)

- North America: 15.6
- Latin America & the Caribbean: 11.4
- Western & Central Europe: 19
- Sub-Saharan Africa: 27.3
- Asia: 8.4
- Oceania: 630,000

**Total Participants:** 552

**Trial Participants, 2018**

### Trial Participants by Prevention Research Area

- Preventative vaccines: 2.3%
- Microbicides: 0.8%
- Prevention of vertical transmission: 2.3%
- Pre-exposure prophylaxis: 13.7%
- Treatment as prevention: 79.3%
- Voluntary medical male circumcision: 1.6%

### Key Population Representation in Clinical Trials

- Gay men, men who have sex with men and transgender women: 8.1%
- People who inject drugs/ are incarcerated: 0.1%
- Sex workers: 0.3%
- Women: 48.3%
- Non-KP specific: 43.2%

---

HIV Prevention Research & Development Investments, 2018:
Investing to End the Epidemic
www.hivresourcetracking.org